|
References
| 1. |
U.S. Department of Health and Human Services, Health Care Finance Organization. MEDPAR Inpatient Hospital Datafile, Fiscal Year 1998. Washington DC: Bureau of Data Management and Strategy; 1999: June Update. |
| 2. |
Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale,design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16. |
| 3. |
Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572-80. |
| 4. |
Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157:99-104. |
| 5. |
American Heart Association. Heart disease and stroke statistics-2004 update. Dallas TX: American Heart Association; 2004. |
| 6. |
Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart 2003;89:615-20. |
| 7. |
Felker GM, Adams KF Jr, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003;145(Suppl):S18-25. |
| 8. |
Baig MK, Mahon N, McKenna WJ, Caforio AL, Bonow RO, Francis GS, et al. The pathophysiology of advanced heart failure. Am Heart J 1998;135:S216-30. |
| 9. |
Maisel AS, McCullough PA. Cardiac natriuretic peptides:a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 2003;(Suppl 4):S3-S12. |
| 10. |
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Due P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. |
| 11. |
Baughman KL. B-type natriuretic peptide-a window to the heart. N Engl J Med 2002;347:158-9. |
| 12. |
Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Due P, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-7. |
| 13. |
Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. Impact of age, race, and sex on the ability of B- type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004;147:107 8-84. |
| 14. |
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82. |
| 15. |
Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54. |
| 16. |
Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 2005;45:1667-71. |
| 17. |
Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001;7:21-9. |
| 18. |
Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91. |
| 19. |
Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-41. |
| 20. |
Gackowski A, Isnard R, Golmard JL, Pousset F, Carayon A, Montalescot G, et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004;25:1788-96. |
| 21. |
Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-8. |
| 22. |
Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003;108:2964-6. |
| 23. |
Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004;6:355-8. |
| 24. |
Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004;126:1330-6. |
| 25. |
Mark DB, Felker GM. B-type natriuretic peptide-a biomarker for all seasons? N Engl J Med 2004;350:718-20. |
| 26. |
Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797-804. |
| 27. |
Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J 2005;26:644-9. |
| 28. |
Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8. |
| 29. |
Gheorghiade M, Gattis WA, Adams KF Jr, Jaffe AS, O'Connor CM. A prospective randomized study of nesiritide versus dobutamine in decompensated heart failure (PRESERVED-HF): Design and preliminary data. J Card Fail 2003;9:S63. |
| 30. |
Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996;94:2285-96. |
| 31. |
Schulz R, Rose J, Martin C, Brodde OE, Heusch G. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993;88:684-95. |
| 32. |
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202. |
| 33. |
Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-7. |
| 34. |
Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-8. |
| 35. |
Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-41. |
| 36. |
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35. |
| 37. |
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93. |
| 38. |
Verma SP, Silke B, Hussain M, Nelson GI, Reynolds GW, Richmond A, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol 1987;10:38-46. |
| 39. |
Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:l-6. |
| 40. |
Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95. |
| 41. |
Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 1986;74:1303-8. |
| 42. |
Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) 1980;59:443-9. |
| 43. |
Schrier RW, Martin PY Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol 1998;449:415-26. |
| 44. |
Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994;71:146-50. |
| 45. |
Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376-82. |
| 46. |
Marenzi G, Agostoni P. Hemofiltration in heart failure. Int J Artif Organs 2004;27:1070-6. |
| 47. |
Jaski BE, Ha J, Denys BG, Lamba S, Trupp RJ, Abraham WT. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 2003;9:227-31. |
| 48. |
Costanzo MR, Saltzberg M, O'Sullivan J, Kotsos T. EUPHORIA trial: Early ultrafiltration therapy in patients with decompensated heart failure and observed resistance to intervention with diuretic agents. J Card Fail 2004;10(Suppl):S78. |
| 49. |
Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, et al. Randomized controlled trial of ultrafiltration versus usual care for hospitalized patients with heart failure: preliminary report of the Rapid Trial. J Card Fail 2004;10(Suppl):S23. |
| 50. |
Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME- CHF) study. Circulation 2005;111:2454-60. |
| 51. |
Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther 2004;9:227-41. |
| 52. |
Parker JD. Counterregulatory responses: sustained-release isosorbide- 5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol 1996;28:631-8. |
| 53. |
Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-31. |
| 54. |
Elkayam U, Group VS. Superior hemodynamic effect of nesiritide (B- type natriuretic peptide) compared to high dose nitroglycerine (NTG) in patients with decompensated heart failure. In: NAIP Fifth Annual Meeting; 2002. p. 7. |
| 55. |
Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994;8:489-99. |
| 56. |
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8. |
| 57. |
Johnston GD. Use of oganic nitrates in the treatment of heart failure. Fund Cardiovasc Pharm 1999;6:140-2. |
| 58. |
Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44. |
| 59. |
Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:896-901. |
| 60. |
Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9. |
| 61. |
Mills RM, LeJemtel TH, Morton DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double- blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-62. |
| 62. |
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40. |
| 63. |
Colucci WS, Elkayam U, Morton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53. |
| 64. |
Wang DJ, Dowling TC, Meadows D, AyalaT, Marshall J, Minshall S, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620-5. |
| 65. |
Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91. |
| 66. |
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5. |
| 67. |
Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93. |
| 68. |
Adams KF Jr, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998;135:S204-15. |
| 69. |
Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Heart Lung 2000;29:16-32. |
| 70. |
Cohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 1982;306:1129-35. |
| 71. |
Bairn DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, et al. Evaluation of a new bipyridine inotropic agent-mil- rinone-in patients with severe congestive heart failure. N Engl J Med 1983;309:748-56. |
| 72. |
Chen EP, Bittner HB, Davis RD, Van Trigt P. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J Heart Lung Transplant 1998;17:669-78. |
| 73. |
Monrad ES, Bairn DS, Smith HS, Lanoue AS. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986;73:III168-74. |
| 74. |
Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J 2001;141:266-73. |
| 75. |
Fonarow GC, Adams KF Jr, Strausser BP, for the ADHERE Scientific Advisory Committee and Investigators. ADHERE (Acute Decompensate Heart Failure National Registry): Rationale, design, and subject population. J Card Fail 2002;8(Suppl):S49. |
| 76. |
Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003. |
| 77. |
Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GC, Hamilton MA, Moriguchi JD, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997;96:1165-72. |
| 78. |
Shah MR, O'Connor CM, Sopko G, Hasselblad V, Califf RM, Stevenson LW. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. Am Heart J 2001;141:528-35. |
| 79. |
Binanay C, Califf RM, Hasselblad V, O'Connor CME, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery Catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-33. |
| 80. |
Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002;288:3115-23. |
|
|
